Tags

Type your tag names separated by a space and hit enter

[Once-weekly teriparatide treatment on osteoporosis].
Clin Calcium. 2014 Jan; 24(1):100-5.CC

Abstract

Teriparatide (human PTH 1-34) transiently stimulate both bone formation and bone resorption and subsequently bone formation markers increased. The changes in bone turnover markers 24 h after each injection of once-weekly 56.5μg teriparatide were constant for 24 weeks. Once-weekly injections of teriparatide increased bone mineral density by 8.1% at the lumbar spine and reduced the risk of new vertebral fracture with a relative risk reduction of 80% compared to placebo for the patients with osteoporosis. Significant vertebral fracture risk reductions were also observed in the patients with high risk for fracture such as higher age, low bone mineral density, or sever vertebral fracture grade. Once-weekly teriparatide improved cortical bone parameters at proximal femur, may have the potential to prevent hip fracture. The duration of teriparatide treatment was limited. Therefore subsequent treatment for osteoporosis should be need. Bisphosphonates seem to be a useful choice as a subsequent treatment to once-weekly teriparatide.

Authors+Show Affiliations

Tamana Central Hospital, Japan.

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

24369286

Citation

Nakano, Tetsuo. "[Once-weekly Teriparatide Treatment On Osteoporosis]." Clinical Calcium, vol. 24, no. 1, 2014, pp. 100-5.
Nakano T. [Once-weekly teriparatide treatment on osteoporosis]. Clin Calcium. 2014;24(1):100-5.
Nakano, T. (2014). [Once-weekly teriparatide treatment on osteoporosis]. Clinical Calcium, 24(1), 100-5. https://doi.org/CliCa1401100105
Nakano T. [Once-weekly Teriparatide Treatment On Osteoporosis]. Clin Calcium. 2014;24(1):100-5. PubMed PMID: 24369286.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Once-weekly teriparatide treatment on osteoporosis]. A1 - Nakano,Tetsuo, PY - 2013/12/27/entrez PY - 2013/12/27/pubmed PY - 2014/5/3/medline SP - 100 EP - 5 JF - Clinical calcium JO - Clin Calcium VL - 24 IS - 1 N2 - Teriparatide (human PTH 1-34) transiently stimulate both bone formation and bone resorption and subsequently bone formation markers increased. The changes in bone turnover markers 24 h after each injection of once-weekly 56.5μg teriparatide were constant for 24 weeks. Once-weekly injections of teriparatide increased bone mineral density by 8.1% at the lumbar spine and reduced the risk of new vertebral fracture with a relative risk reduction of 80% compared to placebo for the patients with osteoporosis. Significant vertebral fracture risk reductions were also observed in the patients with high risk for fracture such as higher age, low bone mineral density, or sever vertebral fracture grade. Once-weekly teriparatide improved cortical bone parameters at proximal femur, may have the potential to prevent hip fracture. The duration of teriparatide treatment was limited. Therefore subsequent treatment for osteoporosis should be need. Bisphosphonates seem to be a useful choice as a subsequent treatment to once-weekly teriparatide. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/24369286/[Once_weekly_teriparatide_treatment_on_osteoporosis]_ L2 - https://www.diseaseinfosearch.org/result/9059 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.